Celgene Maintains Earnings Promises, But Jolts The Balance Sheet And Returns


However, the balance sheet was levered up, and Return on Capital Invested took a hit in order to maintain aggressive growth aspirations. Recently, bio-pharma heavyweight Celgene Corp. reported another set of solid 4Q and full-year results.



from Biotech News